BR112019009029A2 - anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico - Google Patents

anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico

Info

Publication number
BR112019009029A2
BR112019009029A2 BR112019009029A BR112019009029A BR112019009029A2 BR 112019009029 A2 BR112019009029 A2 BR 112019009029A2 BR 112019009029 A BR112019009029 A BR 112019009029A BR 112019009029 A BR112019009029 A BR 112019009029A BR 112019009029 A2 BR112019009029 A2 BR 112019009029A2
Authority
BR
Brazil
Prior art keywords
combination
immune checkpoint
checkpoint inhibitors
therapeutic use
bag3 antibodies
Prior art date
Application number
BR112019009029A
Other languages
English (en)
Inventor
Caterina Turco Maria
De Laurenzi Vincenzo
Marzullo Liberato
Rosati Alessandra
Original Assignee
Biouniversa S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa S.R.L. filed Critical Biouniversa S.R.L.
Publication of BR112019009029A2 publication Critical patent/BR112019009029A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção se refere a uma combinação que compreende anticorpos anti-bag3 e inibidores do ponto de verificação imune, a formulação farmacêutica compreendendo a referida combinação, opcionalmente com um excipiente farmaceuticamente aceitável e à sua utilização no tratamento de doenças neoplásicas.
BR112019009029A 2016-11-07 2017-11-06 anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico BR112019009029A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000111877A IT201600111877A1 (it) 2016-11-07 2016-11-07 Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
PCT/EP2017/078264 WO2018083282A1 (en) 2016-11-07 2017-11-06 Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use

Publications (1)

Publication Number Publication Date
BR112019009029A2 true BR112019009029A2 (pt) 2019-08-06

Family

ID=58609718

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019009029A BR112019009029A2 (pt) 2016-11-07 2017-11-06 anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico

Country Status (12)

Country Link
US (1) US20190263911A1 (pt)
EP (1) EP3535296A1 (pt)
JP (1) JP2020500179A (pt)
KR (1) KR20190072599A (pt)
CN (1) CN109923127A (pt)
AU (1) AU2017352553A1 (pt)
BR (1) BR112019009029A2 (pt)
CA (1) CA3042992A1 (pt)
IL (1) IL266116A (pt)
IT (1) IT201600111877A1 (pt)
MX (1) MX2019005309A (pt)
WO (1) WO2018083282A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946380A4 (en) * 2019-04-01 2022-12-21 Houn Simon Hsia COMPOSITIONS AND METHODS FOR IMMUNO-CANCER THERAPY
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
WO2021214905A1 (ja) * 2020-04-22 2021-10-28 アステラス製薬株式会社 抗ヒトＦｎ１４抗体と免疫チェックポイント阻害剤を併用することにより、がんを予防又は治療する医薬組成物及び方法
WO2022171121A1 (zh) * 2021-02-10 2022-08-18 同润生物医药(上海)有限公司 治疗肿瘤的方法和组合

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1323733A1 (en) 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
IT1397083B1 (it) 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
ITMI20130403A1 (it) * 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合

Also Published As

Publication number Publication date
IL266116A (en) 2019-06-30
IT201600111877A1 (it) 2018-05-07
AU2017352553A1 (en) 2019-05-09
MX2019005309A (es) 2019-10-09
EP3535296A1 (en) 2019-09-11
US20190263911A1 (en) 2019-08-29
WO2018083282A1 (en) 2018-05-11
CA3042992A1 (en) 2018-05-11
CN109923127A (zh) 2019-06-21
KR20190072599A (ko) 2019-06-25
JP2020500179A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
BR112018003984A2 (pt) anticorpos
CL2018001646A1 (es) Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma. (divisional solicitud 201602105)
SV2018005610A (es) Derivados de oxopiridina sustituidos
BR112018010018A2 (pt) moduladores de ror-gama
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
BR112019009029A2 (pt) anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
UY37456A (es) Inmunoglobulinas y sus usos
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
BR112017008416A2 (pt) ?produtos terapêuticos à base de lantionina sintetase c-like 2?.
TN2015000402A1 (fr) Methods for treating crohn's disease using an anti-il23 antibody
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
CL2019001337A1 (es) Formulaciones farmacéuticas.
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
EP4253419A3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2695 DE 30-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.